ReviewTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2016
Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow.
Review in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04372979 (Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.), which is not on this map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.Nature communications · 2022Pooled it
- Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials.Heart & lung : the journal of critical carePooled it
- Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.European journal of internal medicine · 2022Trial
- Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.BMJ open respiratory research · 2021Trial
- Trial
- Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.Vox sanguinis · 2025Article
- Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19.Current research in microbial sciences · 2025Article
- A Roadmap for the Application of Convalescent Plasma and Hyperimmune Globulins in Emerging Viral Outbreaks.TheScientificWorldJournal · 2025Review
- Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.Virology journal · 2024Observational
- Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.Immunologic research · 2024Review
- Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients with COVID-19: The Co-CLARITY Trial.Acta medica Philippina · 2024Article
- Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2023Article
- Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.Process biochemistry (Barking, London, England) · 2023Review
- Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No Detectable Neutralizing Antibodies Nab) in Kashmir, India.Healthcare (Basel, Switzerland) · 2023Article
- Immunomodulation Effect of Convalescent Plasma Therapy in Severe - Critical COVID-19 Patients.Open access emergency medicine : OAEM · 2023Article
- Pharmacokinetics of convalescent plasma therapy in a COVID-19 patient with X-linked Agammaglobulinemia.Clinical immunology communications · 2022Article
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study.BMC pregnancy and childbirth · 2022Article
- SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma therapy consists in bringing to a patient in need - in general suffering a severe, resistant to current therapy, and even lethal infection - plasma or specific, fractioned, antibodies, along with other immunoglobulins and possibly healing factors that can be obtained from immunized blood donors; donors (voluntary and benevolent) can be either actively immunized individuals or convalescent persons. Plasma therapy has been used since the Spanish flu in 1917-1918, and regularly then when viral epidemics threatened vulnerable populations, the last reported occurrence being the 2013-2015 Ebola virus outbreak in West Africa. The precise action mechanism of plasma therapy is not fully delineated as it may function beyond purified, neutralizing antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.